‘Milestone’ funding for Rua Bioscience
Medicinal cannabis company Rua Bioscience has received milestone funding from Callaghan Innovation to support new research.
The $376,000 grant will reinforce the company's projected $1.25m investment into plant science and product development (a requirement of the backing) and fund projects critical to the company's quest to create superior medicinal cannabis products unique to the market.
Rua Bioscience chief research officer Dr Jessika Nowak said Rua would deploy Callaghan Innovation's funding across the company's value chain.
“The funding will support one project feeding into a range of innovative ventures from cultivation to packaging. Those projects include the identification of high-performing commercial cultivars developed by our world-class cultivation team in Ruatorea; the existing hyperspectral imaging project, which looks to revolutionise crop management practice; advancements in CO2 extraction; packaging innovations to improve the quality and stability of Rua products; and DNA tracking and protection of unique Rua cultivars.”
Rua Bioscience chief executive Rob Mitchell said the funding would accelerate specific “future-focused” projects.
“While we'll get pharmaceutical-grade product to market as quickly as we can, we are looking at innovations right across the value chain to create exceptional products that prescribers and patients around the world actively seek out.
“Our relationship with Callaghan Innovation means we can accelerate our bid to create premium quality Rua branded products for a global market with valuable and defendable points of difference,” he said.
Rua recently received GMP (good manufacturing progress) certification and announced the company would have product available for New Zealand patients early next calendar year, and expects to export product to Germany by the close of 2022.